---
document_datetime: 2025-04-11 10:38:59
document_pages: 18
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/revestive-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
document_name: revestive-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
version: success
processing_time: 12.609714
conversion_datetime: 2025-12-24 22:31:12.147685
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Revestive

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                                                                                                                                                          | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary                           |
|----------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------------------------------|
| PSUSA/9305/ 202408   | Periodic Safety Update EU Single assessment - teduglutide                                                                                                                      | 10/04/2025                          | n/a                                         |                                  | PRAC Recommendation - maintenance |
| IA/0065/G            | This was an application for a group of variations. A.7 - Administrative change - Deletion of manufacturing sites A.7 - Administrative change - Deletion of manufacturing sites | 19/09/2024                          | n/a                                         |                                  |                                   |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| II/0064            | Update of section 4.4 of the SmPC in order to add the recommendation of upper GI endoscopy or other imaging before and during the treatment with teduglutide as a precaution to 'Gastrointestinal neoplasia including hepatobiliary tract' based on the cumulative review of literature. Furthermore, section 4.8 is updated with information about location of the small intestinal polyps. In addition, the MAH took the opportunity to introduce minor editorial changes and to bring the PI in line with the latest QRD template. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data   | 04/07/2024   |     | SmPC   | The MAH has evaluated the safety signal (small intestinal polyps and evaluation of the need to perform upper GI endoscopy') for teduglutide and propose to include need for upper endoscopy in the SmPC. The evaluation of the safety signal regarding teduglutide and small intestinal polyps and the need for monitoring of upper GI was initiated following a published scientific paper (de Dreuille et al. 2023). This observational, retrospective study included 35 adult teduglutide treated SBS patients for more than or equal to one year between 2009 and 2022. Out of 35 patients, 10 (28%) patients were identified with polypoid lesions. The polyps were observed 11 to 66 months after teduglutide initiation. In 8 out of the 10 patients, the lesion was found in the small bowel (the duodenal bulb (n=4), duodenum (n=1), ampulla (n=1), and distal jejunum (n=2)). The publication highlighted the importance of performing follow-up upper and lower GI endoscopy in short bowel syndrome patients treated with teduglutide and the potential need to make changes to the recommendations with respect to treatment initiation and follow-up. Based on the evidence from various sources, the need for inclusion of further instructions to perform an upper GI monitoring in section 4.4 as well as the update of section   |
|--------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|-----|--------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| PSUSA/9305/ 202308 | Periodic Safety Update EU Single assessment - teduglutide                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | 11/04/2024   | n/a |        | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| IB/0063            | B.I.z - Quality change - Active substance - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | 14/03/2024   | n/a |        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |

<div style=\"page-break-after: always\"></div>

| II/0054/G          | This was an application for a group of variations.                                                                                                                                                                                                                                                                                                                   | 26/04/2023   | 19/06/2023   | SmPC, Annex II and PL            | Please refer to Scientific Discussion 'Revestive-H-C- 002345-II-0054-G'   |
|--------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|----------------------------------|---------------------------------------------------------------------------|
| PSUSA/9305/ 202208 | Periodic Safety Update EU Single assessment - teduglutide                                                                                                                                                                                                                                                                                                            | 16/03/2023   | n/a          |                                  | PRAC Recommendation - maintenance                                         |
| IAIN/0061/G        | This was an application for a group of variations. B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release - Not including batch control/testing A.1 - Administrative change - Change in the name and/or address of the MAH | 28/02/2023   | 19/06/2023   | SmPC, Annex II, Labelling and PL |                                                                           |

<div style=\"page-break-after: always\"></div>

| IB/0059            | B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place                                                                                                                                                                                                                                            | 11/08/2022   | n/a        |                        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
|--------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| N/0058             | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                                                                                      | 25/07/2022   | 19/06/2023 | PL                     |                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| T/0057             | Transfer of Marketing Authorisation                                                                                                                                                                                                                                                                                                                                                                                   | 22/03/2022   | 17/05/2022 | SmPC, Labelling and PL |                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| PSUSA/9305/ 202108 | Periodic Safety Update EU Single assessment - teduglutide                                                                                                                                                                                                                                                                                                                                                             | 07/04/2022   | n/a        |                        | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| II/0055            | B.II.b.1.c - Replacement or addition of a manufacturing site for the FP - Site where any manufacturing operation(s) take place, except batch release/control, and secondary packaging, for biol/immunol medicinal products or pharmaceutical forms manufactured by complex manufacturing processes                                                                                                                    | 07/04/2022   | n/a        |                        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| II/0053            | Update of sections 4.2, 4.8, 5.1 and 5.2 of the SmPC in order to update the Product information with results from two studies included in the paediatric investigation plan (PIP). Study SHP633-301 was performed to evaluate the safety, efficacy/pharmacodynamics (PD), and pharmacokinetics (PK) of teduglutide in infants 4 to 12 months gestational age with short bowel syndrome (SBS) and who are dependent on | 11/11/2021   | 16/12/2021 | SmPC and PL            | Please refer to Scientific Discussion 'Revestive-H-C- 002345-II-0053' In a completed clinical trial (SHP633-301) in paediatric subjects aged 4 to 12 months corrected gestational age with short bowel syndrome (SBS) dependent on parenteral support (PS), a total of 10 subjects were randomized to the teduglutide arm (n=5) and Standard of Care arm (SOC, n=5), of which 8 subjects completed the study. Overall, results showed a relatively higher number of subjects |

<div style=\"page-break-after: always\"></div>

|           | parenteral support. The second study is a paediatric population PK model including data from study SHP633-301. The Package Leaflet was updated accordingly. In addition, the MAH took the opportunity to make editorial changes to section 4.5 of the SmPC. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data   |            |     | achieving clinically meaningful reductions in PS nutrition volume, caloric intake and a higher percentage of the average reductions in PS calories, daily infusion time an number of days per week in PS usage within the teduglutide arm than the SOC arm. No subject achieved enteral autonomy during the study. Adverse events reported in the study were consistent with the safety profile seen in the previous paediatric studies and no new safety issues were identified. Population pharmacokinetics (PK) and PK/PD modelling and simulation of teduglutide demonstrated Cmax similarity across age groups (4 months to 17 years) supporting 0.05 mg daily dosing in pediatric subjects who are 4 months to less than 1 year of age. A 50% dosage reduction is recommended in paediatric patients with moderate to severe renal impairment and end stage renal disease (ESRD) as adult patients with same degrees of renal impairment. Currently available data in children below 1 year are described in section 5.1 and 5.2, but no recommendation on a posology can be made. Long-term safety data are not yet available for the paediatric population.   |
|-----------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0052/G | This was an application for a group of variations. B.I.a.2.c - Changes in the manufacturing process of the AS - The change refers to a [-] substance in the manufacture of a biological/immunological substance which may have a significant impact on the medicinal product and is not related to a protocol                                                                   | 22/04/2021 | n/a |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |

<div style=\"page-break-after: always\"></div>

|                    | B.I.a.4.a - Change to in-process tests or limits applied during the manufacture of the AS - Tightening of in-process limits                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |            |            |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
|--------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| PSUSA/9305/ 202008 | Periodic Safety Update EU Single assessment - teduglutide                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | 09/04/2021 | n/a        |             | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| PSUSA/9305/ 201908 | Periodic Safety Update EU Single assessment - teduglutide                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | 26/03/2020 | 20/05/2020 | SmPC and PL | Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation(s)' for PSUSA/9305/201908.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| II/0050            | Submission of an updated RMP version 9 in order to update the list of safety concerns. In addition, as advised during procedure EMEA/H/C/PSA/S/0023, an updated protocol for study TED-R13-002 (adding a minor editorial clarification), version 6.0 is provided. The requested variation proposed amendments to the Risk Management Plan (RMP). C.I.11.b - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Implementation of change(s) which require to be further substantiated by new additional data to be submitted by the MAH where significant assessment is required | 16/01/2020 | n/a        |             | Based on a cumulative review of safety data (from post- marketing, clinical studies and literature), antibody response in patients exposed to teduglutide is minimal and there is no significant association of formation of antibodies with events of hypersensitivity or lack of efficacy. For CRP, based on a cumulative review of safety data, there is no evidence to suggest a clinically significant increase in CRP is attributable to teduglutide. Patients with SBS are at risk for non-specific CRP elevations due to increased risk of inflammatory states including environmental infections, central line infections and Crohn's disease exacerbations. As a consequence, the important identified risk 'Occurrence of anti-teduglutide antibodies, cross reactivity with GLP-2 and occurrence of anti-ECP antibodies' and the important potential risk 'Increased CRP' were deleted from the RMP. In addition, important identified risks were renamed for clarity to 'Biliary events', 'Pancreatic events' and 'Intestinal polyps' and an editorial clarification to study |
| IAIN/0047          | B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | 10/05/2019 | n/a        |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |

<div style=\"page-break-after: always\"></div>

|                    | Replacement or addition of a manufacturer responsible for importation and/or batch release - Not including batch control/testing                                                                                                                                                                                                                                                                                                                                                                                                     |            |            |             |                                                                 |
|--------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|-----------------------------------------------------------------|
| PSUSA/9305/ 201808 | Periodic Safety Update EU Single assessment - teduglutide                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | 14/03/2019 | n/a        |             | PRAC Recommendation - maintenance                               |
| II/0043            | Update of sections 4.2, 4.4, 4.8 and 5.1 of the SmPC based on the final CSR of study TED-C14-006 (a 24- Week Double-blind, Safety, Efficacy, and Pharmacodynamic Study Investigating Two Doses of Teduglutide in Pediatric Subjects Aged 1 Year Through 17 Years With Short Bowel Syndrome who are Dependent on Parenteral Support); this is a category 3 study in the RMP. The Package Leaflet is updated accordingly. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance | 13/12/2018 | 31/01/2019 | SmPC and PL | Please refer to Scientific Discussion 'EMEA/H/C/000687/II/0043' |
| II/0045            | C.I.11.b - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Implementation of change(s) which require to be further substantiated by new additional data to be submitted by the MAH where significant assessment is required                                                                                                                                                                                                                                       | 20/09/2018 | n/a        |             |                                                                 |
| IA/0044/G          | This was an application for a group of variations. A.7 - Administrative change - Deletion of manufacturing sites                                                                                                                                                                                                                                                                                                                                                                                                                     | 28/05/2018 | n/a        |             |                                                                 |

<div style=\"page-break-after: always\"></div>

|                    | B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place                                                                                                                                                                                           |            |            |                                  |                                                                                                                                                                                                                                                                               |
|--------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| PSUSA/9305/ 201708 | Periodic Safety Update EU Single assessment - teduglutide                                                                                                                                                                                                                                                                                                            | 08/03/2018 | n/a        |                                  | PRAC Recommendation - maintenance                                                                                                                                                                                                                                             |
| IAIN/0042/G        | This was an application for a group of variations. A.1 - Administrative change - Change in the name and/or address of the MAH B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release - Not including batch control/testing | 22/01/2018 | 23/01/2019 | SmPC, Annex II, Labelling and PL |                                                                                                                                                                                                                                                                               |
| IB/0041/G          | This was an application for a group of variations. B.II.f.1.b.1 - Stability of FP - Extension of the shelf life of the finished product - As packaged for sale (supported by real time data) B.II.f.1.b.1 - Stability of FP - Extension of the shelf life of the finished product - As packaged for sale (supported by real time data)                               | 04/01/2018 | 23/01/2019 | SmPC                             |                                                                                                                                                                                                                                                                               |
| II/0037            | Update of section 4.2 of the SmPC in order to maintain recommended treatment length of 6 months with the addition that there might be late- responders for whom an extended evaluation period of 12 month is appropriate based on literature                                                                                                                         | 14/09/2017 | 19/10/2017 | SmPC                             | Limited data from clinical studies have shown that some patients may take longer to respond to treatment (i.e., those who still have presence of colon in continuity or distal/terminal ileum); if no overall improvement is achieved after 12 months, the need for continued |

<div style=\"page-break-after: always\"></div>

|                    | references. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data                                                                                                                                                                                                                                                                                                                                                                                                                                             |            |            |                        | treatment should be reconsidered.                                                                                                                                                                                                                                       |
|--------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| PSUSA/9305/ 201702 | Periodic Safety Update EU Single assessment - teduglutide                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | 28/09/2017 | n/a        |                        | PRAC Recommendation - maintenance                                                                                                                                                                                                                                       |
| R/0038             | Renewal of the marketing authorisation.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | 21/04/2017 | 23/06/2017 | SmPC, Labelling and PL | Based on the review of data on quality, safety and efficacy, the CHMP considered that the benefit-risk balance of Revestive in the approved indication remains favourable and therefore recommended the renewal of the marketing authorisation with unlimited validity. |
| X/0029             | Annex I_2.(c) Change or addition of a new strength/potency                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | 21/04/2017 | 23/06/2017 | SmPC, Labelling and PL |                                                                                                                                                                                                                                                                         |
| II/0036/G          | This was an application for a group of variations. Submission of 7 non-clinical study reports comprising the in vitro pharmacodynamic study 19498 and the pharmacokinetic studies 8248957, 8248958, TED- P10-007, P10-005, XGW00009, V7674M-SHP633; the final study report of the 2-year mouse carcinogenicity study P09-002/8214171 was also submitted at CHMP request. C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority C.I.13 - Other variations not specifically covered | 18/05/2017 | n/a        |                        |                                                                                                                                                                                                                                                                         |

<div style=\"page-break-after: always\"></div>

|         | elsewhere in this Annex which involve the submission of studies to the competent authority C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission   |            |            |             |                                                                                                                                                                                                                                                                                                                                                             |
|---------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0035 | B.II.d.2.c - Change in test procedure for the finished product - Substantial change to or replacement of a biol/immunol/immunochemical test method or a method using a biol. reagent or replacement of a biol. reference preparation not covered by an approved protocol                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | 23/03/2017 | n/a        |             |                                                                                                                                                                                                                                                                                                                                                             |
| II/0032 | Update of sections 4.3, 4.4, and 4.8 of the SmPC in order to update the safety information in line with the updated CCDS following review of the MAH's safety database. The Package Leaflet is updated accordingly. In addition, the Marketing authorisation holder (MAH) took the opportunity to make minor editorial                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | 23/03/2017 | 23/06/2017 | SmPC and PL | Revestive is contraindicated in patients with a history of malignancies in the gastrointestinal tract, including the hepatobiliary system and pancreas within the last five years. Fluid overload has been observed in clinical trials. Fluid overload adverse events occurred most frequently during the first 4 weeks of therapy and decreased over time. |

<div style=\"page-break-after: always\"></div>

|                    | changes in section 5.1 of the SmPC. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data   |            |            |                     | Congestive heart failure has been observed in clinical trials. The most commonly reported adverse reactions were abdominal pain and distension (45%), respiratory tract infections (28%) (including nasopharyngitis, influenza, upper respiratory tract infection, and lower respiratory tract infection), nausea (26%), injection site reactions (26%), headache (16%), and vomiting (14%). Based on integrated data from two trials in adults with SBS (a 6 month randomised placebo controlled trial, followed by a 24 month open label trial), the development of anti teduglutide antibodies in subjects who received subcutaneous administration of 0.05 mg/kg teduglutide once daily was 3% (2/60) at Month 3, 17% (13/77) at Month 6, 24% (16/67) at Month 12, 33% (11/33) at Month 24, and 48% (14/29) at Month 30. Injection site reactions occurred in 26% of SBS patients treated with Revestive, compared to 5% of patients in the placebo arm. The reactions included injection site haematoma, injection site erythema, injection site pain, injection site swelling and injection site haemorrhage. The majority of reactions were moderate in severity and no occurrences led to drug discontinuation.   |
|--------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|---------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| PSUSA/9305/ 201608 | Periodic Safety Update EU Single assessment - teduglutide                                                                                               | 09/03/2017 | n/a        |                     | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| II/0034            | C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority           | 26/01/2017 | n/a        |                     |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| IB/0031/G          | This was an application for a group of variations.                                                                                                      | 28/10/2016 | 23/06/2017 | SmPC, Labelling and |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |

<div style=\"page-break-after: always\"></div>

|                    | B.II.e.5.a.1 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change within the range of the currently approved pack sizes B.II.e.5.a.2 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change outside the range of the currently approved pack sizes                                         |            |            | PL                     |                                                                                                    |
|--------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|----------------------------------------------------------------------------------------------------|
| PSUSA/9305/ 201602 | Periodic Safety Update EU Single assessment - teduglutide                                                                                                                                                                                                                                                                                                                                                                                      | 29/09/2016 | n/a        |                        | PRAC Recommendation - maintenance                                                                  |
| T/0030             | Transfer of Marketing Authorisation from NPS Pharma Holdings Limited to Shire Pharmaceuticals Ireland Limited. Transfer of Marketing Authorisation                                                                                                                                                                                                                                                                                             | 01/08/2016 | 25/08/2016 | SmPC, Labelling and PL |                                                                                                    |
| II/0020            | Extension of Indication to include the treatment of patients aged 1 year and above with short bowel Syndrome who are stable following a period of intestinal adaptation. As a consequence, sections 4.1, 4.2, 4.4, 4.8, 5.1, 5.2 and 6.6 of the SmPC are updated. The Package Leaflet is updated in accordance. C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or modification of an approved one | 26/05/2016 | 29/06/2016 | SmPC, Annex II and PL  | Please refer to the scientific discussion Revestive EMEA/H/C/002345/II/20 for further information. |
| IAIN/0028          | B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP -                                                                                                                                                                                                                                                                                                                                          | 28/06/2016 | 25/08/2016 | Annex II and           |                                                                                                    |

<div style=\"page-break-after: always\"></div>

|                    | Replacement or addition of a manufacturer responsible for importation and/or batch release - Not including batch control/testing                                                                                                                                                                                                                                                                                                                                          |            |     | PL   |                                   |
|--------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|------|-----------------------------------|
| PSUSA/9305/ 201508 | Periodic Safety Update EU Single assessment - teduglutide                                                                                                                                                                                                                                                                                                                                                                                                                 | 17/03/2016 | n/a |      | PRAC Recommendation - maintenance |
| IB/0026/G          | This was an application for a group of variations. B.II.b.5.c - Change to in-process tests or limits applied during the manufacture of the finished product - Deletion of a non-significant in-process test B.II.b.5.z - Change to in-process tests or limits applied during the manufacture of the finished product - Other variation                                                                                                                                    | 12/02/2016 | n/a |      |                                   |
| IAIN/0024          | C.I.8.a - Introduction of or changes to a summary of Pharmacovigilance system - Changes in QPPV (including contact details) and/or changes in the PSMF location                                                                                                                                                                                                                                                                                                           | 09/12/2015 | n/a |      |                                   |
| IA/0022/G          | This was an application for a group of variations. B.I.a.4.a - Change to in-process tests or limits applied during the manufacture of the AS - Tightening of in-process limits B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure B.II.c.3.a.1 - Change in source of an excipient or reagent with TSE risk - From TSE risk material to vegetable or synthetic origin - For excipients or | 28/10/2015 | n/a |      |                                   |

<div style=\"page-break-after: always\"></div>

|                    | reagents NOT used in the manufacture of a biol/immunol AS or in a biol/immunol medicinal product                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |            |            |                        |                                   |
|--------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|-----------------------------------|
| PSUSA/9305/ 201502 | Periodic Safety Update EU Single assessment - teduglutide                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | 10/09/2015 | n/a        |                        | PRAC Recommendation - maintenance |
| IAIN/0021          | A.1 - Administrative change - Change in the name and/or address of the MAH                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | 20/08/2015 | 11/11/2015 | SmPC, Labelling and PL |                                   |
| IAIN/0019          | C.I.8.a - Introduction of or changes to a summary of Pharmacovigilance system - Changes in QPPV (including contact details) and/or changes in the PSMF location                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | 16/07/2015 | n/a        |                        |                                   |
| IAIN/0018/G        | This was an application for a group of variations. B.II.d.2.f - Change in test procedure for the finished product - To reflect compliance with the Ph. Eur. and remove reference to the outdated internal test method and test method number B.II.b.2.z - Change to importer, batch release arrangements and quality control testing of the FP - Other variation B.II.b.5.a - Change to in-process tests or limits applied during the manufacture of the finished product - Tightening of in-process limits B.II.d.1.h - Change in the specification parameters and/or limits of the finished product - Update of the dossier to comply with the provisions of an updated general monograph of the Ph. Eur. for the finished | 25/06/2015 | n/a        |                        |                                   |

<div style=\"page-break-after: always\"></div>

|                    | product                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |            |            |                                  |                                   |
|--------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------------------------------|-----------------------------------|
| II/0009            | Submission of the revised RMP (version 6.4) in order to include the results of long-term study CL0600-021 and to include updated review of non-clinical risks, clinical exposure data and post-marketing exposure data. C.I.11.b - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Implementation of change(s) which require to be further substantiated by new additional data to be submitted by the MAH where significant assessment is required | 21/05/2015 | n/a        |                                  |                                   |
| II/0016            | B.I.a.1.j - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Replacement or addition of a site where batch control/testing takes place and any of the test method at the site is a biol/immunol method                                                                                                                                                                                                                                                                         | 26/03/2015 | n/a        |                                  |                                   |
| PSUSA/9305/ 201408 | Periodic Safety Update EU Single assessment - teduglutide                                                                                                                                                                                                                                                                                                                                                                                                                                                              | 12/03/2015 | n/a        |                                  | PRAC Recommendation - maintenance |
| N/0015             | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                                                                                                                                                                                       | 19/01/2015 | 11/11/2015 | PL                               |                                   |
| IB/0012/G          | This was an application for a group of variations. B.II.f.1.b.5 - Stability of FP - Extension of the shelf life of the finished product - Biological/immunological medicinal product in accordance with an approved                                                                                                                                                                                                                                                                                                    | 26/11/2014 | 11/11/2015 | SmPC, Annex II, Labelling and PL |                                   |

<div style=\"page-break-after: always\"></div>

|           | stability protocol B.II.f.1.d - Stability of FP - Change in storage conditions of the finished product or the diluted/reconstituted product B.II.f.1.e - Stability of FP - Change to an approved stability protocol A.7 - Administrative change - Deletion of manufacturing sites                                                                                                                                                                                               |            |     |                                   |
|-----------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-----------------------------------|
| IA/0013/G | This was an application for a group of variations. B.II.b.5.b - Change to in-process tests or limits applied during the manufacture of the finished product - Addition of a new test(s) and limits B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place B.I.a.4.z - Change to in-process tests or limits applied during the manufacture of the AS - Other | 19/11/2014 | n/a |                                   |
| PSUV/0008 | Periodic Safety Update                                                                                                                                                                                                                                                                                                                                                                                                                                                          | 09/10/2014 | n/a | PRAC Recommendation - maintenance |
| IB/0011   | B.I.b.1.z - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Other variation                                                                                                                                                                                                                                                                                                                                             | 08/09/2014 | n/a |                                   |
| IB/0010   | B.II.d.2.d - Change in test procedure for the finished product - Other changes to a test procedure (including replacement or addition)                                                                                                                                                                                                                                                                                                                                          | 20/08/2014 | n/a |                                   |

<div style=\"page-break-after: always\"></div>

| II/0006     | Update of sections 4.2, 4.4, 4.8 and 5.1 of the SmPC with the results of a long term open label study on safety, tolerability and efficacy as requested in Annex II of the MA. The Package Leaflet is updated accordingly. Furthermore, the PI is being brought in line with the latest QRD template version 9.0. The requested variation proposed amendments to the Summary of Product Characteristics, Annex II and Package Leaflet. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data   | 22/05/2014   | 15/12/2014   | SmPC, Annex II and PL   | Following the results of a long-term open label study no new safety signals have been identified in patients exposed to 0.05 mg/kg/day of Revestive for up to 30 months and no clinically relevant mean increases of C-reactive protein from baseline were observed. However, due to the relative high occurrence of gastrointestinal polyps in patients who were treated with Revestive for one to two years, a recommendation to perform follow-up colonoscopies (or alternative imaging) during the first two years of treatment has been included in the product information. Long-term treatment showed continued and/or improved response for up to 2.5 years of continuous therapy and acknowledging that specialized care is customary and SBS patient's response is monitored versus any potential risks of further treatment a recommendation for continuous treatment for patients who have weaned off parenteral nutrition was added in 4.2 of the SmPC.   |
|-------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|-------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| PSUV/0005   | Periodic Safety Update                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | 10/04/2014   | n/a          |                         | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| IG/0421     | C.I.8.a - Introduction of or changes to a summary of Pharmacovigilance system - Changes in QPPV (including contact details) and/or changes in the PSMF location                                                                                                                                                                                                                                                                                                                                                                                            | 21/03/2014   | n/a          |                         |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| IAIN/0004/G | This was an application for a group of variations. B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP -                                                                                                                                                                                                                                                                                                | 20/12/2013   | 15/12/2014   | SmPC, Annex II and PL   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |

<div style=\"page-break-after: always\"></div>

|         | addition of a manufacturer responsible for importation and/or batch release - Not including batch control/testing C.I.12 - Inclusion or deletion of black symbol and explanatory statements for medicinal products in the list of medicinal products that are subject to additional monitoring   |            |            |                        | Replacement or        |
|---------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|-----------------------|
| T/0003  | Transfer of Marketing Authorisation from Nycomed Danmark ApS to NPS Pharma Holdings Limited. Authorisation                                                                                                                                                                                       | 13/09/2013 | 09/10/2013 | SmPC, Labelling and PL | Transfer of Marketing |
| IG/0293 | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                                                                                                                                                   | 23/04/2013 | n/a        |                        |                       |
| IG/0219 | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                                                                                                                                                   | 25/09/2012 | n/a        |                        |                       |